Showing 1 - 6 results of 6 for search 'Lucia Bortot', query time: 0.02s Refine Results
  1. 1
    CDK4/6 Inhibitors as Upfront Treatment in a Patient with Breast Cancer Presenting with a Clinical Critic Situation: A Case Report and Review of the Literature

    CDK4/6 Inhibitors as Upfront Treatment in a Patient with Breast Cancer Presenting with a Clinical Critic Situation: A Case Report and Review of the Literature by Giada Targato, Lucia Bortot, Arianna Dri, Marta Bonotto, Alessandro Marco Minisini, Gianpiero Fasola, Mauro Mansutti

    Published 2022-12-01
    Get full text
    Article
  2. 2
    Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis

    Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis by Michele Bartoletti, Giacomo Pelizzari, Lorenzo Gerratana, Lucia Bortot, Davide Lombardi, Milena Nicoloso, Simona Scalone, Giorgio Giorda, Gustavo Baldassarre, Roberto Sorio, Fabio Puglisi

    Published 2020-05-01
    Get full text
    Article
  3. 3
    Plasma-Based Longitudinal Evaluation of ESR1 Epigenetic Status in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer

    Plasma-Based Longitudinal Evaluation of ESR1 Epigenetic Status in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer by Lorenzo Gerratana, Lorenzo Gerratana, Debora Basile, Debora Basile, Alessandra Franzoni, Lorenzo Allegri, Davide Viotto, Carla Corvaja, Carla Corvaja, Lucia Bortot, Lucia Bortot, Elisa Bertoli, Elisa Bertoli, Silvia Buriolla, Silvia Buriolla, Giada Targato, Giada Targato, Lucia Da Ros, Stefania Russo, Marta Bonotto, Barbara Belletti, Gustavo Baldassarre, Giuseppe Damante, Fabio Puglisi, Fabio Puglisi

    Published 2020-09-01
    Get full text
    Article
  4. 4
    Multidisciplinary Team Meeting Proposal and Final Therapeutic Choice in Early Breast Cancer: Is There an Agreement?

    Multidisciplinary Team Meeting Proposal and Final Therapeutic Choice in Early Breast Cancer: Is There an Agreement? by Lucia Bortot, Lucia Bortot, Giada Targato, Giada Targato, Claudia Noto, Claudia Noto, Marco Giavarra, Lorenza Palmero, Lorenza Palmero, Diego Zara, Diego Zara, Elisa Bertoli, Elisa Bertoli, Arianna Dri, Arianna Dri, Claudia Andreetta, Gaetano Pascoletti, Elena Poletto, Stefania Russo, Luca Seriau, Mauro Mansutti, Carla Cedolini, Debora Basile, Gianpiero Fasola, Marta Bonotto, Alessandro Marco Minisini

    Published 2022-06-01
    Get full text
    Article
  5. 5
    Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside

    Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside by Debora Basile, Paola Di Nardo, Carla Corvaja, Silvio Ken Garattini, Giacomo Pelizzari, Camilla Lisanti, Lucia Bortot, Lucia Da Ros, Michele Bartoletti, Matteo Borghi, Lorenzo Gerratana, Davide Lombardi, Fabio Puglisi

    Published 2019-06-01
    Get full text
    Article
  6. 6
    Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for a Cost-Effective and Dynamic Biomarker

    Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for a Cost-Effective and Dynamic Biomarker by Giacomo Pelizzari, Debora Basile, Silvia Zago, Camilla Lisanti, Michele Bartoletti, Lucia Bortot, Maria Grazia Vitale, Valentina Fanotto, Serena Barban, Marika Cinausero, Marta Bonotto, Lorenzo Gerratana, Mauro Mansutti, Francesco Curcio, Gianpiero Fasola, Alessandro Marco Minisini, Fabio Puglisi

    Published 2019-08-01
    Get full text
    Article

Search Tools: